glp 1 drugs adverse effects Your guide to GLP-1 side Clinical Focus on GLP-1 Agonists
Description
This design ensures spatial separation of the GLP-1 N-terminus from the albumin moiety, preserving receptor-binding capacity and maintaining full biological activity
For example, the LEADER trial showed that Liraglutide significantly reduced the risk of major adverse cardiovascular events (MACE) by 13% and cardiovascular death by 22% in comparison to placebo
88 As diseases of immune dysregulation, disrupted gut barrier integrity and dysbiosis, GLP-1RAs which target this in IBD are an attractive prospect
On a GLP-1 journey
doi: 10.1111/j.1468-3083.2012.04609.x
